Comparing TR Band to Statseal in Conjunction With TR Band

• ClinicalTrials.gov Identifier: NCT03028025
• Recruitment Status: Completed
• First Posted: January 23, 2017
• Results First Posted: March 12, 2018
• Last Update Posted: April 21, 2021
• Sponsor: VA Long Beach Healthcare System
• Information provided by (Responsible Party): Arnold Seto, VA Long Beach Healthcare System

Study Description

Brief Summary:

The primary objectives of this study are to evaluate the performance of StatSeal Advanced used in conjunction with the TR Band (SSA) as compared to the TR Band without SSA (TRB) relative to: the incidence of peri-procedural radial artery occlusion (RAO) at discharge or 24 hours, whichever occurs first, and the Time to Hemostasis (TTH).

Condition or disease	Intervention/treatment	Phase
Arterial Occlusion; Angina Pectoris; Cardiovascular Diseases; Atherosclerosis; Hematoma; Anticoagulant-Induced Bleeding; Coronary Artery Disease	Device: StatSeal; Device: TR Band	Not Applicable

Detailed Description:

This study is a physician initiated, prospective, observational, two arm, randomized study to be performed at up to four experienced 'Radial First' centers (UCSD, UCLA. Arkansas Heart Hospital and LBVA). A maximum of 180 patients having undergone successful radial catheterization will be enrolled in the study, 60 in each arm. 60 patients will be enrolled at the LBVA. Enrollment will continue at each site on discretion of the investigators until each center enrolls a minimum of 30 patients, or a maximum of 180 patients are enrolled. Clinicians will perform the catheterization in accordance with local standard practice, with a minimum of 5,000 units of unfractionated heparin for anticoagulation. At the start of the TRA procedure, prior to radial artery cannulation, a baseline Pleth-ox exam will be performed for all patients and recorded on the CRF. Ulnar compression will be applied to confirm that the radial artery is patent. Patients with a type D pattern exam will be excluded from the study. At the conclusion of a successful transradial procedure, the patient will be randomized to either SSA or TRB, each device applied per protocol & IFU. It is hypothesized that if radial artery compression time can be shortened to 40 minutes or less, the following could result: improved catheterization lab efficiency, greater patient satisfaction and lower complication rates, including RAO, may be improved.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 184 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Health Services Research
• Official Title: Radial Hemostasis is Facilitated With a Potassium Ferrate Hemostatic Patch (Statseal): the Randomized Controlled Statseal With TR Band Assessment Trial (STAT)
• Actual Study Start Date: January 1, 2017
• Actual Primary Completion Date: August 1, 2017
• Actual Study Completion Date: August 1, 2017

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: TR Band Only; TR Band: Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.	Device: TR Band; Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.; Other Name: Hemostasis device
Experimental: Statseal with TR Band; StatSeal: Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.	Device: StatSeal; Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.; Other Name: potassium ferrate disc with topical hydrophilic polymer

Outcome Measures

Primary Outcome Measures :

1. Time to Hemostasis Using the Hemostasis Management System (HMS) [ Time Frame: within 30 min of discharge or after 24 hours ]
   Time to deflation for removal of the TR Band (or TR Band and Statseal) for each group was measured in minutes.

Secondary Outcome Measures :

1. Percent of Patients With Radial Artery Occlusion(RAO) [ Time Frame: within 30 min of discharge or after 24 hours ]
   Radial artery occlusion was monitored for all participants using Barbeau's test and pulse oximetry.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patient undergoing diagnostic angiography or PCI via the radial artery
• Patients with a Barbeau test prior to the procedure showing pattern A,B,or

Exclusion Criteria:

• Use of a radial sheath larger than 6 Fr (a 7Fr-in-6 Glidesheath Slender ® is allowed).
• Use of an anticoagulant other than unfractionated heparin or bivalirudin.
• Any anticipated need for continued anticoagulation post-catheterization. Glycoprotein inhibitors are acceptable.
• Any active treatment with oral anticoagulants continued during course of procedure.
• Presence of arteriovenous dialysis fistula in the ipsilateral arm.
• Any physical deformity or trauma / injury of either wrist that would prevent proper placement or function of the hemostasis band.
• Raynaud's syndrome or known peripheral vascular disease of the forearm.
• Mental incompetence or inability to follow the instructions to complete the study.
• History or presence of Radial Artery Occlusion.
• Barbeau test showing Pattern D.
• Patients undergoing catheterization from the femoral or ulnar artery approach.
• Cardiogenic shock or any clinical instability as assessed by the physician performing the procedure.

Contacts and Locations

Locations

United States, California

Veteran Affairs Long Beach

Long Beach, California, United States, 90822

Sponsors and Collaborators

VA Long Beach Healthcare System

Investigators

• Principal Investigator: Arnold H Seto, M.D.; VA Long Beach Hospital

  Study Documents (Full-Text)

Documents provided by Arnold Seto, VA Long Beach Healthcare System:

Study Protocol  [PDF] September 12, 2016

Statistical Analysis Plan  [PDF] November 1, 2017

More Information

Additional Information:

HTML link to document 

Publications of Results:

Seto AH, Rollefson W, Patel MP, Suh WM, Tehrani DM, Nguyen JA, Amador DG, Behnamfar O, Garg V, Cohen MG. Radial haemostasis is facilitated with a potassium ferrate haemostatic patch: the Statseal with TR Band assessment trial (STAT). EuroIntervention. 2018 Dec 7;14(11):e1236-e1242. doi: 10.4244/EIJ-D-18-00101.

• Responsible Party: Arnold Seto, Chief of Cardiology, VA Long Beach Healthcare System
• ClinicalTrials.gov Identifier: NCT03028025
• Other Study ID Numbers: MIRB 1427
• First Posted: January 23, 2017
• Results First Posted: March 12, 2018
• Last Update Posted: April 21, 2021
• Last Verified: March 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes

Keywords provided by Arnold Seto, VA Long Beach Healthcare System:

radial artery occlusion; time to hemostasis; radial artery; transradial catheterization; TR band; Statseal; hemostasis band; potassium ferrate; percutaneous coronary intervention

Additional relevant MeSH terms:

Cardiovascular Diseases; Coronary Artery Disease; Atherosclerosis; Angina Pectoris; Hematoma; Coronary Disease; Myocardial Ischemia; Heart Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Hemorrhage; Pathologic Processes; Chest Pain; Pain; Neurologic Manifestations; Hemostatics; Coagulants